November 4–5 | Shanghai Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 2026 Future Healthcare Investment Market (FHIM) annual conference at the Shanghai International Convention Center (IMAGE)

InSilico Medicine

November 4–5 | Shanghai Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 2026 Future Healthcare Investment Market (FHIM) annual conference at the Shanghai International Convention Center

Caption

Focusing on AI-driven small molecule R&D practices, Dr. Ren will discuss how generative chemistry coupled with automated experimental loops significantly accelerates the journey from target to preclinical candidate (PCC). Drawing on several of Insilico’s clinical-stage in-house programs, he will illustrate how AI platforms translate "technological advantages" into sustainable pipeline assets and transactable value propositions. Amid a more prudent global capital environment, he will also share actionable perspectives on how innovative drug developers can unlock and realize value through technological differentiation and business development partnerships.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.